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. Modern brain imaging techniques have shed new light on the nature of the underlying brain injury and studies on the neurobiology of and pathology associated with brain development have further explored etiologic mechanisms. For c l assification of CP, use of the four major dimensions of classification listed in table I is recommended. Table: I. Components of CP classification
CAUSATION AND TIMING
Whether there is a clearly i d entified cause, as is usually the case with post-natal CP (e.g. meningitis, head injury) or when brain malformations are present, and the presumed time frame during which the injury occurred, if known.
Prevalence and incidence
The overall prevalence of CP has remained constant in recent years despite increased survival of at-risk preterm infants 3 . In developed countries, the overall estimated prevalence of CP is 2-2.5 cases per 1000 live births. The prevalence of CP among preterm and very preterm infants is substantially higher 4 . In the developing world, the prevalence of CP is not well established but estimates are 1.5-5.6 cases per 1000 live births 5 .
Etiology and risk factors
Upto 50% of CP cases have no identifiable underlying etiology 6 . The etiologies can be classified according to the timing of the insult as prenatal (commonest), natal, or postnatal 7 . Risk factors for CP are multifactorial and can include preterm birth, multiple gestation, intrauterine growth restriction, male sex, low Apgar scores, intrauterine infections, maternal thyroid abnormalities, prenatal strokes, birth asphyxia, maternal methyl mercury exposure, and maternal iodine deficiency 8 . There also seems to be an association between autoimmune and coagulation disorders and CP. Preterm infants are at the highest risk for developing CP. The vulnerable brain is harmed during a critical period of development primarily by known CNS complications of prematurity such as intraventricular hemorrhage (IVH) and periventricular leukomalacia (PVL) 1 . PVL is the strongest and most independent risk factor for the development of CP 9 . A recent study found that cerebral malformations were much more frequent among children with CP than among all live births in the population 10 . Children with cerebral malformations tends to be of greater gestational age and birth weight, or the product of a twin gestation 11 . Study suggests that genetic abnormalities may cause cerebral palsy. For years it was thought that a difficult birth and other perinatal factors were the leading causes of CP. Now, researchers find that the majority of CP cases may in fact be caused by genetic abnormalities. There is a growing body of evidence that suggests mutations in multiple genes are responsible for CP 12 . In about 10-20% of patients CP is acquired postnatally mainly because of brain damage from bacterial meningitis, viral encephalitis, hyperbilirubinemia, motor vehicle collisions, falls or child abuse 13 .
Pathogenesis
Cerebral palsy is restricted to lesions of the brain only. The brain lesions of CP occur from t h e fetal or neonatal period up to early childhood 14 . Insults resulting in neuronal loss can be 1) cortical (pyramidal), resulting in spasticity, 2) basal ganglion (extrapyramidal), resulting in abnormal movements such as choreoathetosis, 3) cerebellar, resulting in hypotonia, or 4) mixed. Spastic CP is the most common type, accounting for up to 75% of cases 15 ; and except in mild cases spastic CP can be readily diagnosed in the first few days of life. A smaller percentage of children with CP demonstrate extrapyramidal (dyskinetic) features, and kernicterus (bilirubin encephalopathy) is the leading cause of extrapyramidal CP 1 . The athetoid form cannot usually be diagnosed early, because one cannot be sure until athetoid movement develops which may not be one or two years after birth. Congenital ataxia cannot be diagnosed until about six months, because it is dependent on certain purposive movement not found before then, but tremor can be diagnosed early certainly by the time the baby is able to sit 8 . Hypotonic cerebral palsy occurs rarely; however, most children progress to other CP subtypes. Mixed CP occurs when the child displays a combination of features, such as spasticity and choreoatheosis 1 . Cerebral injury before the 20th week of gestation can result in a neuronal migration deficit; injury between the 26th and 34th weeks can result in periventricular leukomalacia; injury between the 34th and 40th weeks can result in focal or multifocal cerebral injury 16 . The brain lesions seen in preterm infants include germinal matrix/ intraventricular hemorrhage and white matter damage.
hypoxic ischemic encephalopathy (HIE) occurs in 3-5/1000 live births. Although not responsible for the majority of CP in term infants, HIE still forms the largest single subgroup of neonatal encephalopathy (NE) accounting for around 20% of all cases of cerebral palsy in term infants 17 .
Diagnosis
The diagnosis of cerebral palsy is generally made based on the clinical picture. A comprehensive history for risk factors and genetic background, complete physical and neurological examinations are mandatory for accurate diagnosis. Serial developmental evaluations may be necessary in the young child for proper diagnosis and follow up. The differential diagnosis of cerebral palsy includes metabolic and genetic disorders. Genetic evaluation should be considered in patients with con genital malformations (chromosomes) or evidence of metabolic disorders. The Gross Motor Function Measure (GMFM) is standardized observational instrument designed and validated to measure Gross Motor Function Measure over time in children with cerebral palsy. The 2004 American Academy of Neurology (AAN) practice parameter on CP developed an algorithm for the evaluation of the child with cerebral palsy 18 .
Imaging Studies
Most (83%) children with CP have abnormal neuroradiological findings, with white matter damage the most common abnormality.
a. Cranial ultrasonography performed in the early neonatal period can delineate clear-cut structural abnormalities and show evidence of hemorrhage or hypoxic-ischemic injury. b. CT scanning of the brain helps identify congenital malformations, intracranial hemorrhage, and periventricular leukomalacia in infants more clearly than ultrasonography. c. MRI is preferred over CT scanning because it defines cortical and white matter structures and abnormalities more clearly than any other method. It also allows for the determination of appropriate myelination for a given age 19 . Infants and children can be studied with MRI, and ultrafast MRI permits evaluation of the fetal CNS. Results from fetal MRI have led to better understanding of many brain abnormalities. All children with CP should have an MRI scan to provide information on the timing and extent of the lesion 20 . So, neuroimaging is currently recommended as a standard evaluation in children with CP and MRI is the diagnostic neuroimaging study of choice 21 . 
Management
The management of patients with cerebral palsy must be individualized based on the childs clinical presentation and requires a multidisciplinary approach that provides a combination of interventions 22 . Specific treatment options include physical, occupational and speech therapy, drug treatment for spasticity (local, intrathecal, systemic) and orthopedic and neurosurgical interventions. The primary care physician should provide anticipatory guidance, immunizations, and developmental surveillance 1 . Children with CP are at high risk of incomplete and delayed immunization and their increased vulnerability to the complications of vaccine-preventable diseases 23 . All routine immunization should be provided, including pertussis vaccine, even if the child has epilepsy. Progressive uncontrolled epilepsy indicates DT rather than DPT vaccine. Annual influenza vaccine and pneumococcal immunization is recommended for those with recurrent or chronic respiratory illnesses 1 . Spasticity and other forms of muscle over activity caused by cerebral palsy may impair function or ease of care or may cause discomfort or poor body image. The treatment program for a child with spasticity may include allied health therapy, exercise, casting, constraint-induced therapy, oral medications, chemodenervation, intrathecal baclofen, selective dorsal rhizotomy, and orthopedic surgery. Te c hniques may be combined for greater efficacy and better tailoring to the needs of the child 19 . Systemic treatments for spasticity include Baclofen, Diazepam, Dantrolene and Tizanidine alone or in combination. Baclofen is the most commonly used oral medication in children with generalized spasticity. Children with spasticity that are refractory or intolerant to oral medications may be candidates for intrathecal baclofen therapy. In general, oral medications and intrathecal baclofen are used for treating generalized spasticity, while chemodenervation agents (botulinum toxin, phenol or alcohol) are used to treat localized spasticity 24 .
Chemical denervation
Injection Botulinum toxin type A can be an effective treatment for pain in children with hip spasms and cerebral palsy. With on going active physiotherapy, longer benefits from the injections can occur. A new guideline from the AAN and the child neurology society finds Injection Botulinum toxin type A to be an effective and generally safe treatment for spasticity in children and adolescents with CP but there is some risk of isolated cases of generalized weakness following its use. Chemical denervation u s ing phenol injections are some times used in larger muscles where botulinum toxin would be ineffective. How ever there is insufficient data to support or refute the use of phenol or alcohol 25 .
Non-pharmacological therapy Selective dorsal rhizotomy (SDR) :
Selective dorsal rhizotomy is a well a c cepted neurosurgical procedure for t h e relief of lower limb spasticity in children with spastic diplegic CP 36 . SDR plus physical therapy decreases spasticity, improves joint range of motion and have a positive effect on gross motor function, and gait 26 .
Neuromuscular electrical stimulation (NMES) :
There is evidence to support the use and effectiveness of NMES in children with CP. Electrical stimulation to the hip adductor and abductor muscles simultaneously at the sensory and motor levels respectively improves the gait of spastic diplegic CP children 38 . How ever the use of dynamic splinting with NMES has been shown to be more effective than either treatment along on its own in improving function and posture. A neurostimulation device (the L 300 Foot Drop System), for the treatment of footdrop in children with cerebral palsy, was the first device of its kind approved by the US Food and Drug Administration (FDA) in January 2013 for use in children 27 . Orthotic management in cerebral palsy: Children with CP may have many musculoskeletal deformities depending on the type of CP. Rehabilitation, orthopedic surgical intervention and additional orthotic management can prevent and correct these deformities. Orthoses are frequently used to improve the gait efficiency of ambulant children with CP and the most common orthoses used is the ankle-foot orthoses(AFO) 28 . Rehabilitation: T r aditional Physiotherapy and Occupational therapy are widely used interventions and have been shown to be of benefit in the treatment of cerebral palsy.Children with CP who require intensive physical, occupational and speech therapy may need to be admitted for rehabilitation.These patients receive therapy in at least 2 disciplines for 3 hours daily 29 . Physiotherapy: Physiotherapy is the most common intervention in cerebral palsy and is usually a component of mandated program of management. Physiotherapy program consists of Neuro-developmental Treatment (NDT) and Therapeutic Exercises (TEs) 22 .
Occupational therapy (OT):
Occupational therapy focuses on the development of skills necessary for the performance of activities of daily living. These activities include play, self-care activities such as dressing, grooming and feeding, and fine motor tasks such as writing and drawing. OT also addresses cognitive and perceptual disabilities, especially in the visual-motor area 22 .
Constraint-Induced Movement Therapy:
Researchers report that children with CP who underwent C-I movement therapy saw a significant increase in grey matter volume in areas of the brain associated with movement 30 . Training for sensory and perceptual integration: This is provided by giving various types of sensory stimulation. Most of this training is given in the form of play. Children not only accept this, they often enjoy learning these skills.
Oral medications
Orthopedic Surgery
Botulinum toxin A-B Spacticity
Other non pharmacological therapy Speech/Language Therapy : focuses on talking, using sign language, or using a communication aid 26 .
Intrathecal baclofen

Vagal nerve stimulation (VNS) :
Jaseja has shown the efficacy of VNS in CP patients on account of its dual therapeutic effectiveness, i.e. anti-epileptic and IED-suppression. These two effects are likely to control seizures that are quite often drug-resistant and also improve neurocognition in CP patients, thus hoping for a better overall prognostic outcome and an improved quality of life . Several study showed that vitamin D and a third generation bisphosphonate (risedronate) have a larger increase in bone mineral density compared with children treated with vitamin D alone. Vitamin K : In a child with hemiplegia treated with vitamin K alone, the cortical bone geometric strength of the hemiplegic tibia increased compared with the non-hemiplegic tibia 36 . New advances : In a study, allogenic umbilical cord blood (UCB) infusion potentiated with recombinant human erythropoietin (rhEPO) ameliorated motor and cognitive impairment in children with CP, suggesting that this therapy could be developed as a novel therapeutic approach. A comprehensive evaluation of the adverse effects of this therapy is, however, necessary before its clinical application. Rabbits with CP treated with D-NAC, a dendrimer coupled with a drug known as NAC (N-acetyl-L-cysteine) showed a dramatic improvement and within 5 days were able to walk and hop. While still in pre-clinical testing in animals, the dendrimer-drug conjugate shows promise for postnatal treatment of babies suspected of having CP 37 .
Prognosis
In general, Some children who sit between three and four years of age eventually walk, but most require aids or braces or have restricted functional ambulation. A child who does not walk by nine years of age is unlikely to ever walk, even with support 36 . Overall, the probability of reaching the age of 20 years in child with severe CP is 50%. Respiratory infections, aspiration, epilepsy, and cerebral malformation are leading causes of death 38 .
Conclusion
Various Medical efforts failed to prevent the occurrence of CP. CP is a very diverse diagnosis with substantial variation in impairments and severity. Care and research in childhood CP is evolving. Management is not curative; however, if provided optimally it can improve the quality of life of these children and their families.
